Equities research analysts predict that Nightstar Therapeutics (NASDAQ:NITE) will post ($0.39) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Nightstar Therapeutics’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.29). The business is expected to issue its next quarterly earnings report on Tuesday, July 3rd.
On average, analysts expect that Nightstar Therapeutics will report full year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($2.37) to ($1.16). For the next financial year, analysts anticipate that the company will report earnings of ($1.65) per share, with EPS estimates ranging from ($1.98) to ($1.22). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Nightstar Therapeutics.
Several research analysts have recently issued reports on NITE shares. Chardan Capital started coverage on Nightstar Therapeutics in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 target price for the company. Mizuho started coverage on Nightstar Therapeutics in a research report on Tuesday, February 27th. They issued a “buy” rating and a $20.00 target price for the company. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Nightstar Therapeutics in a research note on Wednesday, March 7th. Finally, Zacks Investment Research downgraded Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 7th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Nightstar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $28.50.
Several institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors purchased a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth approximately $1,196,000. Essex Investment Management Co. LLC purchased a new stake in shares of Nightstar Therapeutics in the 4th quarter worth approximately $1,771,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth approximately $5,761,000. Institutional investors own 29.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/04/23/analysts-anticipate-nightstar-therapeutics-nite-will-post-earnings-of-0-39-per-share.html.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.